Episode Details

Merck posted $16.61B in Q2 revenue and $8.37B in Keytruda sales — then cut profit guidance on acquisition charges. Alex and Maya break down the oral PCSK9 approval, the planned sacituzumab tirumotecan and Keytruda combination trial, and what the 2028 loss of exclusivity forces next. Plus Pfizer's additional $2.5 billion in cost savings and Eliquis strength, the sigvotatug vedotin miss in non-small cell lung cancer, the Oxbryta write-down in sickle cell disease, and BioNTech naming Sobi's Guido Oelkers chief executive as it pivots toward oncology.

Visit us at thepharmacloseout.com.